Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease.
Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Hock C, et al. Among authors: maddalena a. Amyloid. 2003 Mar;10(1):1-6. doi: 10.3109/13506120308995249. Amyloid. 2003. PMID: 12762134 Clinical Trial.
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Hock C, et al. Among authors: maddalena a. Neuron. 2003 May 22;38(4):547-54. doi: 10.1016/s0896-6273(03)00294-0. Neuron. 2003. PMID: 12765607 Free article. Clinical Trial.
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease.
Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM. Hock C, et al. Among authors: maddalena a. Ann N Y Acad Sci. 2000;920:285-91. doi: 10.1111/j.1749-6632.2000.tb06937.x. Ann N Y Acad Sci. 2000. PMID: 11193166 Clinical Trial.
Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease.
Wollmer MA, Papassotiropoulos A, Streffer JR, Grimaldi LM, Kapaki E, Salani G, Paraskevas GP, Maddalena A, de Quervain D, Bieber C, Umbricht D, Lemke U, Bosshardt S, Degonda N, Henke K, Hegi T, Jung HH, Pasch T, Hock C, Nitsch RM. Wollmer MA, et al. Among authors: maddalena a. Psychiatr Genet. 2002 Sep;12(3):155-60. doi: 10.1097/00041444-200209000-00006. Psychiatr Genet. 2002. PMID: 12218659
Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism.
Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lütjohann D, Ghebremedhin E, Hegi T, Pasch T, Träxler M, Brühl A, Benussi L, Binetti G, Braak H, Nitsch RM, Hock C. Papassotiropoulos A, et al. Among authors: maddalena a. Arch Neurol. 2003 Jan;60(1):29-35. doi: 10.1001/archneur.60.1.29. Arch Neurol. 2003. PMID: 12533085
Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease.
Papassotiropoulos A, Lambert JC, Wavrant-De Vrièze F, Wollmer MA, von der Kammer H, Streffer JR, Maddalena A, Huynh KD, Wolleb S, Lutjohann D, Schneider B, Thal DR, Grimaldi LM, Tsolaki M, Kapaki E, Ravid R, Konietzko U, Hegi T, Pasch T, Jung H, Braak H, Amouyel P, Rogaev EI, Hardy J, Hock C, Nitsch RM. Papassotiropoulos A, et al. Among authors: maddalena a. Neurodegener Dis. 2005;2(5):233-41. doi: 10.1159/000090362. Neurodegener Dis. 2005. PMID: 16909003 Free article.
82 results